nach oben

Erschienen in:

2020 | OriginalPaper | Buchkapitel

8. Klassifikationen, Indizes, Aktivitätsbeurteilung

verfasst von : Gerhard Rogler, Luc Biedermann

Erschienen in: Chronisch-entzündliche Darmerkrankungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Klassifikationen und Aktivitätsindizes bei Colitis ulcerosa und Morbus Crohn können klinische Hilfsmittel zur Aktivitätsbeurteilung chronisch-entzündlicher Darmerkrankungen (CED) darstellen. Viele der Indizes sind jedoch recht kompliziert und werden daher häufig nur für klinische Studien gebraucht, um den Effekt einer therapeutischen Intervention möglichst klar quantifizieren zu können. Die therapeutischen Fortschritte, die bei der Behandlung von CED in den letzten Jahren gemacht wurden, und die wachsende Zahl der Optionen, die zur Verfügung stehen, haben die Bedeutung der Beurteilung der Krankheitsaktivität deutlich gesteigert und für den klinischen Alltag relevanter gemacht.

Bessissow T, Lemmens B, Ferrante M, Bisschops R, Van Steen K, Geboes K, Van Assche G, Vermeire S, Rutgeerts P, De Hertogh G (2012) Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 107:1684–1692PubMedCrossRef

Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 70:439–444CrossRefPubMed

Bodger K, Ormerod C, Shackcloth D, Harrison M, Collaborative IBDC (2014) Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut 63:1092–1102PubMedCrossRef

Brant SR, Panhuysen CI, Bailey-Wilson JE, Rohal PM, Lee S, Mann J, Ravenhill G, Kirschner BS, Hanauer SB, Cho JH et al (2000) Linkage heterogeneity for the IBD1 locus in Crohn’s disease pedigrees by disease onset and severity. Gastroenterology 119:1483–1490PubMedCrossRef

Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L (2015) Comparing histological activity indexes in UC. Gut 64:1412–1418PubMedCrossRef

Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S et al (2016) Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 65:408–414PubMedCrossRef

Calabrese E, Zorzi F, Onali S, Stasi E, Fiori R, Prencipe S, Bella A, Petruzziello C, Condino G, Lolli E et al (2013) Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn’s disease. Clin Gastroenterol Hepatol 11:950–955PubMedCrossRef

Corte C, Fernandopulle N, Catuneanu AM, Burger D, Cesarini M, White L, Keshav S, Travis S (2015) Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohn’s Colitis 9:376–381CrossRef

D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lemann M, Marteau P, Rutgeerts P, Scholmerich J et al (2007) A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132:763–786PubMedCrossRef

Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A et al (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60:505–512PubMedCrossRef

Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ et al (2000) A simple classification of Crohn’s disease: report of the working party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6:8–15PubMedCrossRef

Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Lofberg R (2000) A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47:404–409PubMedPubMedCentralCrossRef

Greenstein AJ, Lachman P, Sachar DB, Springhorn J, Heimann T, Janowitz HD, Aufses AH Jr (1988) Perforating and non-perforating indications for repeated operations in Crohn’s disease: evidence for two clinical forms. Gut 29:588–592PubMedPubMedCentralCrossRef

Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T (2007) Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133:1099–1105 quiz 1340–1091PubMedCrossRef

Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C (1989) A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96:804–810PubMedCrossRef

Hanauer SB (1994) Measurements of disease activity. In: Targan SR, Shanahan F (Hrsg) Inflammatory bowel disease, from bench to bedside. Williams & Williams, Baltimore, S 429–444

Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s-disease activity. Lancet 1:514PubMedCrossRef

Irvine EJ (1995) Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD study group. J Clin Gastroenterol 20:27–32PubMedCrossRef

Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW (1994) Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 106:287–296PubMedCrossRef

Irvine EJ, Zhou Q, Thompson AK (1996) The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol 91:1571–1578PubMed

Limberg B (1999) Diagnosis of chronic inflammatory bowel disease by ultrasonography. Z Gastroenterol 37:495–508PubMed

Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J (2001) Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49:777–782PubMedPubMedCentralCrossRef

Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S et al (2017) Development and validation of the Nancy histological index for UC. Gut 66:43–49PubMedCrossRef

Mary JY, Modigliani R (1989) Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30:983–989PubMedPubMedCentralCrossRef

Mosli MH, Feagan BG, Zou G, Sandborn WJ, D’Haens G, Khanna R, Behling C, Kaplan K, Driman DK, Shackelton LM et al (2015) Reproducibility of histological assessments of disease activity in UC. Gut 64:1765–1773PubMedCrossRef

Mosli MH, Feagan BG, Zou G, Sandborn WJ, D’Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK et al (2017) Development and validation of a histological index for UC. Gut 66:50–58PubMedCrossRef

Neurath MF, Travis SP (2012) Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61:1619–1635PubMedCrossRef

Panes J, Bouzas R, Chaparro M, Garcia-Sanchez V, Gisbert JP, Martinez de Guerenu B, Mendoza JL, Paredes JM, Quiroga S, Ripolles T et al (2011) Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther 34:125–145PubMedCrossRef

Parente F, Molteni M, Marino B, Colli A, Ardizzone S, Greco S, Sampietro G, Foschi D, Gallus S (2010) Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol 105:1150–1157PubMedCrossRef

Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B et al (2015) Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110:1324–1338PubMedCrossRef

Powell-Tuck J, Bown RL, Lennard-Jones JE (1978) A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 13:833–837PubMedCrossRef

Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82–86PubMedPubMedCentralCrossRef

Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME (1991) Microscopic activity in ulcerative colitis: what does it mean? Gut 32:174–178PubMedPubMedCentralCrossRef

Rimola J, Ordas I, Rodriguez S, Garcia-Bosch O, Aceituno M, Llach J, Ayuso C, Ricart E, Panes J (2011) Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 17:1759–1768PubMedCrossRef

Rogler G, Vavricka S, Schoepfer A, Lakatos PL (2013) Mucosal healing and deep remission: what does it mean? World J Gastroenterol 19:7552–7560PubMedPubMedCentralCrossRef

Russell RK, Drummond HE, Nimmo EE, Anderson N, Smith L, Wilson DC, Gillett PM, McGrogan P, Hassan K, Weaver LT et al (2005) Genotype-phenotype analysis in childhood-onset Crohn’s disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 11:955–964PubMedCrossRef

Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G (1984) Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 25:665–672PubMedPubMedCentralCrossRef

Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99:956–963PubMedCrossRef

Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W et al (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:402–413PubMedCrossRef

Sachar DB, Andrews HA, Farmer RG (1992) Proposed classification of patient subgroups in Crohn’s disease. Gastroenterol Int 5:141–154

Sachar DB, Subramani K, Mauer K, Rivera-MacMurray S, Turtel P, Bodian CA, Greenstein AJ (1996) Patterns of postoperative recurrence in fistulizing and stenotic Crohn’s disease. A retrospective cohort study of 71 patients. J Clin Gastroenterol 22:114–116PubMedCrossRef

Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, Present DH, Rutgeerts P, Scholmerich J, Stange EF et al (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 122:512–530CrossRefPubMed

Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55:749–753PubMedPubMedCentralCrossRef

Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625–1629PubMedCrossRef

Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F (2010) Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 105:162–169PubMedCrossRef

Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummler M, Pittet V, Vavricka SR (2013) Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 19:332–341PubMedCrossRef

Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K et al (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5–36

Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L (1987) 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894–1898PubMedCrossRef

Tibble JA, Bjarnason I (2001) Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc) 37:85–96CrossRef

Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lemann M, Lichtenstein GR et al (2012) Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 61:535–542PubMedCrossRef

Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR et al (2013) Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 145:987–995PubMedCrossRef

Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2:1041–1048PubMedPubMedCentralCrossRef

Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE et al (2007) Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133:423–432PubMedCrossRef

Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH (2009) A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 7:1081–1088PubMedCrossRef

Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D’Hoore A, Penninckx F, Marchal G, Cornillie F et al (2003) Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 98:332–339PubMedCrossRef

van Hees PAM, van Eltren PH, van Lier HJJ, van Tongerem JHM (1980) An index of inflammatory activity in patients with Crohn’s disease. Gut 21:279–286PubMedPubMedCentralCrossRef

Veloso FT, Ferreira JT, Barros L, Almeida S (2001) Clinical outcome of Crohn’s disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 7:306–313PubMedCrossRef

Walmsley RS, Casey P (2013) On the physician-completed and the patient-completed simple clinical colitis activity index (SCCAI). J Crohn’s Colitis 7:930–931CrossRef

Walmsley RS, Ayres RC, Pounder RE, Allan RN (1998) A simple clinical colitis activity index. Gut 43:29–32PubMedPubMedCentralCrossRef

Walsh AJ, Bryant RV, Travis SP (2016) Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol 13:567–579PubMedCrossRef

Titel: Klassifikationen, Indizes, Aktivitätsbeurteilung
verfasst von: Gerhard Rogler
Luc Biedermann
Verlag: Springer Berlin Heidelberg
Buch: Chronisch-entzündliche Darmerkrankungen
Print ISBN: 978-3-662-59103-1

Electronic ISBN: 978-3-662-59104-8

Copyright-Jahr: 2020
DOI: https://doi.org/10.1007/978-3-662-59104-8_8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen